Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:05 PM
Ignite Modification Date:
2025-12-24 @ 4:05 PM
NCT ID:
NCT02229266
Eligibility Criteria:
Inclusion Criteria:
* Newly diagnosed AML other than acute promyelocytic leukemia (APL) according to WHO criteria
* In AML defined by cytogenetic aberrations the proportion of blasts may be \<20%
* Age ≥60 years
* Clinical performance corresponding to ECOG score 0-2
* High-risk karyotype
* \<5% myeloblasts in bone marrow ≥21 days after beginning of most recent chemotherapy
* maximal two preceding chemotherapy cycles
* Potentially available haploidentical family donor (child/ sibling), willing and fit for NK cell donation
Exclusion Criteria:
* AML with favorable or intermediate risk cytogenetic features
* Persistent aplasia following preceding chemotherapy
* Relapsed or refractory AML
* Known pre-existing autoimmune diseases
* Any severe concomitant condition which makes it undesirable for the patient to participate in the study
* Any condition which could jeorpadize compliance of the protocol
* Participation in another clinical trial during or within 4 weeks before study entry
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
60 Years
Maximum Age:
99 Years
Study:
NCT02229266
Study Brief:
Protocol Section:
NCT02229266